Charles Schwab Investment Management Inc. Sells 714,949 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Charles Schwab Investment Management Inc. lessened its position in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 17.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,497,406 shares of the biotechnology company's stock after selling 714,949 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.51% of OPKO Health worth $5,141,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of OPK. FMR LLC grew its stake in OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock worth $32,000 after buying an additional 11,089 shares during the last quarter. Orion Portfolio Solutions LLC acquired a new stake in shares of OPKO Health during the third quarter worth $45,000. Ieq Capital LLC acquired a new position in shares of OPKO Health during the 4th quarter worth about $52,000. World Investment Advisors LLC bought a new stake in OPKO Health in the third quarter valued at approximately $61,000. Finally, Point72 DIFC Ltd acquired a new stake in OPKO Health during the 3rd quarter worth $71,000. Institutional investors own 64.63% of the company's stock.

Insider Transactions at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 150,000 shares of the firm's stock in a transaction dated Friday, January 17th. The shares were bought at an average price of $1.47 per share, for a total transaction of $220,500.00. Following the purchase, the chief executive officer now owns 213,186,477 shares in the company, valued at approximately $313,384,121.19. This trade represents a 0.07 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders have acquired 1,114,971 shares of company stock valued at $1,748,692. 49.69% of the stock is currently owned by company insiders.

Remove Ads

OPKO Health Stock Performance

OPKO Health stock traded down $0.04 during trading hours on Friday, hitting $1.70. The company had a trading volume of 2,946,540 shares, compared to its average volume of 4,121,305. OPKO Health, Inc. has a one year low of $1.15 and a one year high of $2.04. The firm has a market cap of $1.14 billion, a PE ratio of -8.95 and a beta of 1.70. The firm has a 50-day moving average of $1.68 and a 200 day moving average of $1.58. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The firm had revenue of $183.60 million for the quarter, compared to analysts' expectations of $155.42 million. On average, sell-side analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on OPK. HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price target on shares of OPKO Health in a research note on Wednesday, March 19th. StockNews.com upgraded shares of OPKO Health from a "sell" rating to a "hold" rating in a report on Monday, March 3rd. Finally, Barrington Research reiterated an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a report on Wednesday, March 12th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.